Monday , December 11 2017
Home / Letter From The Editor (page 21)

Letter From The Editor

March 12, 2016

You may have seen a recent study that has brought into question the safety of SPLENDA®, leading to the downgraded safety rating of sucralose by the Center for Science in the Public Interest (CSPI). As we have seen before, these studies seem to find their way in to the press regardless of the credibility associated with …

Read More »

Over the past 30 years that I have been a pharmacist, we have had many sound-alike drugs. Many of you remember when Losec became Prilosec because of the confusion with Lasix. Often we don’t even see these problems unless someone has a bad event. This week our disaster avoided looks …

Read More »

March 5, 2016

Ever since GLP-1 analogs have been available, there have been a lot of worries about cardiovascular problems. Part of this was brought on by Dr. Steven Nissen’s full frontal attack on the TZD’s (later proven to not be true). His angry commentary on the cardiovascular risks of diabetes drugs put …

Read More »

13 years ago we ran an article on diabetes and dental health. Over the years we have added over 100 items on the relationship of diabetes and mouth health, including many by our feature writer, Dr. Frank Varon, DDS. 10 years ago this week he prepared his first feature on diabetes and periodontal …

Read More »

February 27, 2016

The results of the SPRINT trial included 9361 hypertensive patients 50 years of age or older randomized to either a standard systolic blood pressure target of 140 mm Hg or an intensive treatment target of 120 mm Hg.  The primary (composite) outcome was myocardial infarction, other acute coronary syndromes, stroke, …

Read More »

I just spent the day in a conference talking about the genetic differences in different ethnic groups, and how that affects both causes and treatments for diseases such as cancer, congestive heart failure, and hypertension. I personally know how genetics can have an effect, because I lack the proper gene …

Read More »

February 20, 2106

When the SGLT-2 drugs first came out, there was a big emphasis put on the UTI side-effect, and many prescribers were hesitant to try the class. This proved to be over-exaggerated and prescribers started using them. Further research showed that they could cause weight loss and lower blood pressure, and …

Read More »

According to IMS prescribing data, all of the SGLT-2 inhibitor class drugs are experiencing growth. What is more important is that the 6-month adherence rate is higher than any other branded class. Part of this can be attributed to the 2-year free medication vouchers that all manufacturers offer. However, if …

Read More »

This past week, we had our 3rd endocrinologist retire since December. We have a metropolitan population of just under 3 million people, and now we are down to 17 endocrinologists — and 6 of them only take care of children. Eleven endos for 3 million people is just hard to believe. If …

Read More »

February 13, 2016

Last week, I had a little blurb about the Dubai Tour and Team Novo Nordisk. Eight riders, all with type 1 diabetes, headed to the United Arab Emirates for their first Tour de France quality race of the year. Team veteran Javier Megias was Team Novo Nordisk’s best-placed rider, finishing …

Read More »